Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir 12-week versus longer-duration regimen in genotype 1 chronic hepatitis C with IL28B CC genotype
2011-001323-21Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telaprevir, interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: SVR12 in T12/PR12 arm. Started Oct 2011; status: completed.
02
Drugs
telaprevirinterferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-001323-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001323-21.